Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903789 | 1.00 | BTK (0.52) | BTKKITFLT3EGFRLCK | |
| SCHEMBL21965766 | 0.92 | BTK (0.49) | BTKKITFLT3EGFRLCK | |
| SCHEMBL31684271 | 0.92 | BTK (0.49) | BTKKITFLT3EGFRLCK | |
| SCHEMBL21903689 | 0.92 | BTK (0.49) | BTKKITFLT3EGFRLCK | |
| SCHEMBL21903774 | 0.91 | BTK (0.46) | BTKEGFRITK | |
| SCHEMBL21903780 | 0.91 | BTK (0.46) | BTKEGFRITK | |
| SCHEMBL21903653 | 0.89 | BTK (0.51) | BTKITK | |
| SCHEMBL21903559 | 0.89 | BTK (0.51) | BTKITK | |
| SCHEMBL21903564 | 0.89 | BTK (0.51) | BTKITK | |
| SCHEMBL21903730 | 0.88 | BTK (0.51) | BTKKITFLT3EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-11-23 | — | — | US | disclosed |
| EP-3653626-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-05-20 | — | — | EP | disclosed |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
| CN-110914266-A | Novel 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | 株式会社大熊制药 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | PDCD11, DPYD, G6PC1 | BTK 1236/4885KIT 2970/4885FLT3 408/4885 |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD11, G6PC1, PPM1D | BTK 1744/4885KIT 3133/4885FLT3 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.